Antibodies to pyroglutamate amyloid-β and uses thereof

1. An isolated monoclonal antibody or antigen-binding fragment thereof comprising a heavy complementarity determining region 1 (HCDR1), HCDR2, HCDR3, and a light chain complementarity determining region 1 (LCDR1), LCDR2, and LCDR3, having the polypeptide sequences of:

a. SEQ ID NOs: 1, 2, 3, 4, 5, and 6, respectively;

b. SEQ ID NOs: 1, 7, 3, 4, 5, and 6, respectively;

c. SEQ ID NOs: 1, 7, 3, 8, 5, and 6, respectively;

d. SEQ ID NOs: 1, 2, 3, 8, 5, and 6, respectively;

e. SEQ ID NOs: 56, 57, 3, 8, 5, and 6, respectively;

f. SEQ ID NOs: 56, 57, 3, 4, 5, and 6, respectively;

g. SEQ ID NOs: 56, 58, 3, 4, 5, and 6, respectively;

h. SEQ ID NOs: 56, 7, 3, 8, 5, and 6, respectively;

i. SEQ ID NOs: 1, 57, 3, 8, 5, and 6, respectively;

j. SEQ ID NOs: 56, 7, 3, 4, 5, and 6, respectively;

k. SEQ ID NOs: 1, 57, 3, 4, 5, and 6, respectively;

l. SEQ ID NOs: 1, 58, 3, 4, 5, and 6, respectively; or

m. SEQ ID NOs: 56, 2, 3, 4, 5, and 6, respectively;

wherein the antibody or antigen-binding fragment thereof specifically binds amyloid-β peptide having pyroglutamate at the third residue (3pE Aβ).

2. The isolated monoclonal antibody or antigen-binding fragment thereof of claim 1 , comprising a heavy chain variable region having a polypeptide sequence at least 95% identical to SEQ ID NO: 9, 11, 13, 15, 16, 17, 19, 20, or 21, or a light chain variable region having a polypeptide sequence at least 95% identical to SEQ ID NO: 10, 12, 14, 18, 22, 53, or 55.

3. The isolated monoclonal antibody or antigen-binding fragment thereof of claim 1 , comprising:

a. a heavy chain variable region having the polypeptide sequence of SEQ ID NO:21, and a light chain variable region having the polypeptide sequence of SEQ ID NO:22;

b. a heavy chain variable region having the polypeptide sequence of SEQ ID NO:9, and a light chain variable region having the polypeptide sequence of SEQ ID NO:10;

c. a heavy chain variable region having the polypeptide sequence of SEQ ID NO:11, and a light chain variable region having the polypeptide sequence of SEQ ID NO:12;

d. a heavy chain variable region having the polypeptide sequence of SEQ ID NO:13, and a light chain variable region having the polypeptide sequence of SEQ ID NO:14;

e. a heavy chain variable region having the polypeptide sequence of SEQ ID NO:15, and a light chain variable region having the polypeptide sequence of SEQ ID NO:14;

f. a heavy chain variable region having the polypeptide sequence of SEQ ID NO:16, and a light chain variable region having the polypeptide sequence of SEQ ID NO:14;

g. a heavy chain variable region having the polypeptide sequence of SEQ ID NO:20, and a light chain variable region having the polypeptide sequence of SEQ ID NO:14;

h. a heavy chain variable region having the polypeptide sequence of SEQ ID NO:17, and a light chain variable region having the polypeptide sequence of SEQ ID NO:18;

i. a heavy chain variable region having the polypeptide sequence of SEQ ID NO:19, and a light chain variable region having the polypeptide sequence of SEQ ID NO:18;

j. a heavy chain variable region having the polypeptide sequence of SEQ ID NO:21, and a light chain variable region having the polypeptide sequence of SEQ ID NO:53; or

k. a heavy chain variable region having the polypeptide sequence of SEQ ID NO:21, and a light chain variable region having the polypeptide sequence of SEQ ID NO:55.

4. The isolated monoclonal antibody or antigen-binding fragment thereof of any one of claims 1 - 3 , wherein the antibody or antigen-binding fragment thereof is chimeric.

5. The isolated monoclonal antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody or antigen-binding fragment thereof is humanized.

6. The isolated monoclonal antibody or antigen-binding fragment thereof of claim 1 , wherein the isolated monoclonal antibody or antigen-binding fragment thereof specifically binds human-3pE Aβ.

7. An isolated nucleic acid encoding the monoclonal antibody or antigen-binding fragment thereof of claim 1 .

8. A vector comprising the isolated nucleic acid of claim 7 .

9. A host cell comprising the vector of claim 8 .

10. An isolated monoclonal antibody comprising:

a. a heavy chain amino acid sequence comprising SEQ ID NO:37 and a light chain amino acid sequence comprising SEQ ID NO:38;

b. a heavy chain amino acid sequence comprising SEQ ID NO:39 and a light chain amino acid sequence comprising SEQ ID NO:38;

c. a heavy chain amino acid sequence comprising SEQ ID NO:37 and a light chain amino acid sequence comprising SEQ ID NO:52;

d. a heavy chain amino acid sequence comprising SEQ ID NO:39 and a light chain amino acid sequence comprising SEQ ID NO: 52;

e. a heavy chain amino acid sequence comprising SEQ ID NO:37 and a light chain amino acid sequence comprising SEQ ID NO:54; or

f. a heavy chain amino acid sequence comprising SEQ ID NO:39 and a light chain amino acid sequence comprising SEQ ID NO:54.

11. A method of producing the monoclonal antibody or antigen-binding fragment thereof of claim 1 , comprising culturing a cell comprising a nucleic acid encoding the monoclonal antibody or antigen-binding fragment thereof under conditions to produce the monoclonal antibody or antigen-binding fragment thereof, and recovering the antibody or antigen-binding fragment thereof.

12. A method of producing a pharmaceutical composition comprising the monoclonal antibody or antigen-binding fragment thereof of claim 1 , the method comprising combining the monoclonal antibody or antigen-binding fragment thereof with a pharmaceutically acceptable carrier to obtain the pharmaceutical composition.

13. A pharmaceutical composition comprising the monoclonal antibody or antigen binding fragment thereof of claim 1 and a pharmaceutically acceptable carrier.

14. A method of treating a condition associated with the formation of plaques containing beta-amyloid protein in a subject in need thereof, the method comprising administering the pharmaceutical composition of claim 13 to the subject in need thereof.

15. The method of claim 14 , wherein the condition is Alzheimer's disease.

16. The method of claim 14 , wherein the condition is selected form the group consisting of dementia associated with Trisomy 21 (Down's Syndrome), diffuse Lewy body disease, inclusion body myositis, cerebral amyloid angiopathy and hereditary cerebral hemorrhage with amyloidosis of the Dutch-type (HCHWA-D).

17. A method of reducing plaques associated with Alzheimer's disease in a subject in need thereof, the method comprising administering the pharmaceutical composition of claim 13 to the subject in need thereof.

18. A method of preventing seeding activity of 3pE Aβ in a subject in need thereof, the method comprising administering the pharmaceutical composition of claim 10 to the subject in need thereof.

19. A method of treating a condition associated with the formation of plaques containing beta-amyloid protein in a subject in need thereof, the method comprising administering the isolated monoclonal antibody or antigen binding fragment thereof of claim 1 to the subject in need thereof.

20. The method of claim 19 , wherein the condition is Alzheimer's disease.

21. The method of claim 19 , wherein the condition is selected from the group consisting of dementia associated with Trisomy 21 (Down's Syndrome), diffuse Lewy body disease, inclusion body myositis, cerebral amyloid angiopathy, and hereditary cerebral hemorrhage with amyloidosis of the Dutch-type (HCHWA-D).

22. A method of reducing plaques associated with Alzheimer's disease in a subject in need thereof, the method comprising administering the isolated monoclonal antibody or antigen-binding fragment thereof of claim 1 to the subject in need thereof.

23. A method of preventing seeding activity of 3pE Aβ in a subject in need thereof, the method comprising administering the isolated monoclonal antibody or antigen-binding fragment thereof of claim 1 to the subject in need thereof.